Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer

Keiichi Koshizuka; Daiju Sakurai; Miki Sunagane; Yukiyoshi Mita; Sawako Hamasaki; Takeshi Suzuki; Naoko Kikkawa; Michiyo Nakano; Toyoyuki Hanazawa

doi:10.1002/ccr3.3695

Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer

Clin Case Rep. 2020 Dec 18;9(2):848-852. doi: 10.1002/ccr3.3695. eCollection 2021 Feb.

Authors

Keiichi Koshizuka¹, Daiju Sakurai², Miki Sunagane¹, Yukiyoshi Mita¹, Sawako Hamasaki¹, Takeshi Suzuki¹, Naoko Kikkawa¹, Michiyo Nakano³, Toyoyuki Hanazawa¹

Affiliations

¹ Department of Otorhinolaryngology/Head and Neck Surgery Chiba University Graduate School of Medicine Chiba Japan.
² Department of Otolaryngology, Head and Neck Surgery University of Yamanashi Kofu Japan.
³ Department of Dermatology Chiba University Graduate School of Medicine Chiba Japan.

Abstract

This report is the first to document TEN caused by nivolumab treatment in head and neck cancer. We believe this article can contribute significantly in understanding the principles of nivolumab treatment in patients with head and neck cancer.

Keywords: Stevens‐Johnson syndrome; head and neck cancer; nivolumab; toxic epidermal necrolysis.

Publication types

Case Reports